Evidence map›Paper›PMID 25358095›Full record

Trial reportInternational journal of environmental research and public health2014

Effectiveness of the electronic cigarette: An eight-week Flemish study with six-month follow-up on smoking reduction, craving and experienced benefits and complaints.

Karolien Adriaens, Dinska Van Gucht, Paul Declerck, Frank Baeyens

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in International journal of environmental research and public health, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04231838 (A Randomised Controlled International Multicentre Study Evaluating Changes in Metabolic Syndrome in Smokers With Type 2 Diabetes Mellitus After Switching From Tobacco Cigarettes to Combustion-Free Nicotine Delivery Systems), which is not on this map. Cited by 126 papers, 20 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed, 20 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04231838 naunknown statusnot on this mapstarted 2021, after this paper: background citation

A Randomised Controlled International Multicentre Study Evaluating Changes in Metabolic Syndrome in Smokers With Type 2 Diabetes Mellitus After Switching From Tobacco Cigarettes to Combustion-Free Nicotine Delivery Systems: DIASMOKE Study

TypeinterventionalSponsorEclat Srl.Ran2021 to 2026Enrolled576ConditionsCardiovascular Risk Factor, Diabetes Mellitus, Type 2ArmsTOBACCO CIGARETTES, COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)
3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 20 syntheses or guidelines pooled it.

  1. Electronic cigarettes for smoking cessation.The Cochrane database of systematic reviews · 2026
    Pooled it
  2. Pooled it
  3. Electronic cigarettes for smoking cessation.The Cochrane database of systematic reviews · 2025
    Pooled it
  4. Recommendations on interventions for tobacco smoking cessation in adults in Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Guideline
  5. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Guideline
  6. Pooled it
  7. Electronic cigarettes for smoking cessation.The Cochrane database of systematic reviews · 2025
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Electronic cigarettes for smoking cessation.The Cochrane database of systematic reviews · 2024
    Pooled it
  11. Electronic cigarettes for smoking cessation.The Cochrane database of systematic reviews · 2022
    Pooled it
  12. Pooled it
  13. Electronic cigarettes for smoking cessation.The Cochrane database of systematic reviews · 2021
    Pooled it
  14. Electronic cigarettes for smoking cessation.The Cochrane database of systematic reviews · 2021
    Pooled it
  15. Electronic cigarettes for smoking cessation.The Cochrane database of systematic reviews · 2020
    Pooled it
  16. Pooled it
  17. Pooled it
  18. Overview of Electronic Nicotine Delivery Systems: A Systematic Review.American journal of preventive medicine · 2017
    Pooled it
  19. Interventions to reduce harm from continued tobacco use.The Cochrane database of systematic reviews · 2016
    Pooled it
  20. Pooled it

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Karolien AdriaensFaculty of Psychology and Educational Sciences, KU Leuven-University of Leuven, Tiensestraat 102, 3000 Leuven, Belgium. karolien.adriaens@hotmail.com.
Dinska Van GuchtFaculty of Psychology and Educational Sciences, KU Leuven-University of Leuven, Tiensestraat 102, 3000 Leuven, Belgium. dinska.vangucht@thomasmore.be.
Paul DeclerckDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven-University of Leuven, O&N II Herestraat 49, 3000 Leuven, Belgium. paul.declerck@pharm.kuleuven.be.
Frank BaeyensFaculty of Psychology and Educational Sciences, KU Leuven-University of Leuven, Tiensestraat 102, 3000 Leuven, Belgium. frank.baeyens@ppw.kuleuven.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSmoking reduction remains a pivotal issue in public health policy, but quit rates obtained with traditional quit-smoking therapies remain disappointingly low. Tobacco Harm Reduction (THR), aiming at less harmful ways of consuming nicotine, may provide a more effective alternative. One promising candidate for THR are electronic cigarettes (e-cigs). The aim of this study was to investigate the efficacy of second-generation e-cigs both in terms of acute craving-reduction in the lab and in terms of smoking reduction and experienced benefits/complaints in an eight-month Randomized Controlled Trial (RCT).

designRCT with three arms.

methodsParticipants (N = 48) unwilling to quit smoking were randomized into two e-cig groups and one control group. During three lab sessions (over two months) participants, who had been abstinent for four hours, vaped/smoked for five minutes, after which we monitored the effect on craving and withdrawal symptoms. eCO and saliva cotinine levels were also measured. In between lab sessions, participants in the e-cig groups could use e-cigs or smoke ad libitum, whereas the control group could only smoke. After the lab sessions, the control group also received an e-cig. The RCT included several questionnaires, which repeatedly monitored the effect of ad libitum e-cig use on the use of tobacco cigarettes and the experienced benefits/complaints up to six months after the last lab session.

resultsFrom the first lab session on, e-cig use after four hours of abstinence resulted in a reduction in cigarette craving which was of the same magnitude as when a cigarette was smoked, while eCO was unaffected. After two months, we observed that 34% of the e-cig groups had stopped smoking tobacco cigarettes, versus 0% of the control group. After five months, the e-cig groups demonstrated a total quit-rate of 37%, whereas the control group showed a quit rate of 38% three months after initiating e-cig use. At the end of the eight-month study, 19% of the e-cig groups and 25% of the control group were totally abstinent from smoking, while an overall reduction of 60% in the number of cigarettes smoked per day was observed (compared to intake). eCO levels decreased, whereas cotinine levels were the same in all groups at each moment of measurement. Reported benefits far outweighed the reported complaints.

conclusionIn a series of controlled lab sessions with e-cig naïve tobacco smokers, second generation e-cigs were shown to be immediately and highly effective in reducing abstinence induced cigarette craving and withdrawal symptoms, while not resulting in increases in eCO. Remarkable (>50 pc) eight-month reductions in, or complete abstinence from tobacco smoking was achieved with the e-cig in almost half (44%) of the participants.

Indexed as

Smoking CessationAdultBelgiumBiomarkersCarbon DioxideCotinineCravingElectronic Nicotine Delivery SystemsFemaleFollow-Up StudiesHumansMaleMiddle AgedNicotineSalivaSubstance Withdrawal SyndromeBiomarkersCarbon DioxideCotinineNicotine

Identifiers

PMID25358095
PMCPMC4245610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.